190908-91-9

Upstream product

• 56583-58-5 N-tert-butoxycarbonyl-3-(2-naphthyl)-L-alanine 
• 74-89-5 methylamine 
• 593-51-1 methylamine hydrochloride 

Downstream Products

• 190908-93-1 (R)-N⁴-Benzyloxy-2-isobutyl-N¹-((S)-1-methylcarbamoyl-2-naphthalen-2-yl-ethyl)-succinamide 
• 848671-21-6 3-[[(S)-2-(3-Benzyloxy-benzylamino)-4-methyl-pentanoyl]-((S)-1-methylcarbamoyl-2-naphthalen-2-yl-ethyl)-amino]-propionic acid 
• 848671-57-8 (S)-4-Methyl-2-[[2-((S)-1-methylcarbamoyl-2-naphthalen-2-yl-ethylamino)-acetyl]-(4-pyridin-3-yl-benzyl)-amino]-pentanoic acid tert-butyl ester 
• 848671-62-5 (S)-4-Methyl-2-[[2-((S)-1-methylcarbamoyl-2-naphthalen-2-yl-ethylamino)-acetyl]-(4-pyridin-3-yl-benzyl)-amino]-pentanoic acid 
• 848671-27-2 3-[[(S)-2-(4-Dimethylamino-benzylamino)-4-methyl-pentanoyl]-((S)-1-methylcarbamoyl-2-naphthalen-2-yl-ethyl)-amino]-propionic acid 
• 848671-53-4 (S)-2-{(4-Bromo-benzyl)-[2-((S)-1-methylcarbamoyl-2-naphthalen-2-yl-ethylamino)-acetyl]-amino}-4-methyl-pentanoic acid tert-butyl ester 
• 848671-19-2 3-[[(S)-2-(4-Bromo-benzylamino)-4-methyl-pentanoyl]-((S)-1-methylcarbamoyl-2-naphthalen-2-yl-ethyl)-amino]-propionic acid 
• 848671-59-0 (S)-2-{(4-Bromo-benzyl)-[2-((S)-1-methylcarbamoyl-2-naphthalen-2-yl-ethylamino)-acetyl]-amino}-4-methyl-pentanoic acid 
• 848671-17-0 3-[((S)-2-Benzylamino-4-methyl-pentanoyl)-((S)-1-methylcarbamoyl-2-naphthalen-2-yl-ethyl)-amino]-propionic acid 

Relevant academic research and scientific papers

Melanocortin receptor ligands

Disclosed are MC-4 and/or MC-3 receptor ligands, the ligands having a structure according to Formula (I): wherein R2, R4, R4′, R5, R6, R6′, R7, R8, R8′, R9, R9′, R10, Ar, Z1, Z2, Z3, X, B, D, p, q, r and s are as described in the specification and claims, and optical isomers, diastereomers or enantiomers thereof; pharmaceutically-acceptable salts, hydrates, and biohydrolyzable esters, amides or imides thereof. Also disclosed are pharmaceutical compositions comprising the ligands of Formula (I), as well as methods of treating diseases mediate by the MC-4/MC-3 receptors, as described in the Detailed Descriptions section of the specification.

1,4-Diazepane-2,5-diones as novel inhibitors of LFA-1

1,4-Diazepane-2,5-diones (2) are found to be a new class of potent LFA-1 inhibitors. The synthesis, structure, and biological evaluation of these 1,4-diazepine-2,5-diones and related derivatives are described.

Matrix metalloproteinase inhibitors: A structure-activity study

Modifications around the dipeptide-mimetic core of a hydroxamic acid based matrix metalloproteinase inhibitor were studied. These variations incorporated a variety of natural, unnatural, and synthetic amino acids inaddition to modifications of the P1' and P3' substituents. The results of this study indicate the following structural requirements: (2) Potent inhibitorsmust possess string zinc-binding functionalities. (3) The potential importance of the hydrophobic group at position R3 as illustratedby itsability to impart greater relative potency against stromelysin when larger hydrophobic groups are used. (4) Requirements surrounding the nature of the amino acid appear to be more restrictive for stromelysin than for neutrophil collagenase, 72 kDa gelatinase, and 92 kDa gelatinase. These requirements may involve planar fused-ring aryl systems and possibly hydrogen-bonding capabilities.

Synthesis and biological evaluation of orally active matrix metaloproteinase inhibitors

The synthesis and biological evaluation of orally active inhibitors of matrix metalloproteinase are reported. Modifications of the P2' position and the α-substituent of hydroxamic acid derivatives were carried out, and revealed that the P2' substituent influenced the MMP inhibitory activities in vitro and in plasma after oral administration. The hydroxamates with phenylglycine at the P2' position were absorbed well orally. Compound 15e, which exhibited the longest duration of inhibitory activity in plasma after oral administration among the phenylglycine derivatives (5a-5d, 15a, 15c, 15e), was evaluated in a rat adjuvant arthritis model. A reduction in hind foot pad swelling and improvements of some inflammatory parameters were demonstrated when the compound was administered orally. These results indicate the potential of MMP inhibitors for rheumatoid arthritis.